OKAPI VENTURE CAPITAL,

Managing Directors

B. Marc Averitt

Marc is a Co-Founder and Managing Director of Okapi Venture Capital and is responsible for Okapi Ventures' technology and digital media investments. He has held leadership positions of increasing responsibility in business development, legal, operations, corporate development, and strategy in the technology industry since the mid-90s. Prior to founding Okapi, Marc was with Intel Corporation first as an attorney for the Microprocessor Products Group and then as the Managing Director, Strategic Business Development for the Software & Solutions Group worldwide. Prior to Intel, Marc worked for Sun Microsystemsin business development and legal roles. Marc received his bachelors from the University of Southern California, where he studied philosophy and business, and went on to earn his Juris Doctor from Pepperdine University School of Law.  He also attended the Stanford University Graduate School of Business executive education program.  Marc's past board affiliations include DATAllegro (acquired by MSFT), TrueEcho, Jabez, and SecondVoice while his present board affiliations include My Damn Channel, RF Nano Corporation, Transaction Wireless, and Welltok. He is also on the Advisory Board of the University of California, Irvine’s Don Beall Center for Innovation & Entrepreneurship.  Marc maintains a personal blog about being a VC in “The OC" at http://ocvcblog.com and can be followed as “OCVC” on Twitter .  Marc lives with his wife and two kids in Orange County, CA and is active with his kids’ school and the local community.

Sharon Stevenson, DVM PhD

Sharon is a Co-Founder and Managing Director of Okapi Venture Capital and focuses on Okapi Ventures' life science investments. Sharon was responsible for Okapi’s investment in Helixis (acq: ILMN), and serves as a Director on the boards of Okapi portfolio companies OrthAlign, Obalon Therapeutics, PathCentral, and WellTok.  Prior to founding Okapi, Sharon was the Senior Vice President of Technology and Planning for SkinMedica - a private, venture-backed, commercial stage specialty pharmaceutical company focused on the dermatology and human appearance markets. Prior to SkinMedica, Sharon was a Principal with Domain Associates, LLC - a venture capital fund specializing in life science investments. In addition to performing due diligence and working closely with portfolio companies while at Domain, she also served as President and CFO of Volcano Therapeutics (Nasdaq: VOLC) and lead the company's growth from 1 to 14 employees and from the initial design of the first product to the first clinical trials using the device. In addition to her responsibilities at Volcano, Sharon's past and present board affiliations on behalf of Domain include MicroVention (acquired by Terumo Corporation, OTC: TRUMF.PK), Neuropace, NuVasive (Nasdaq: NUVA), Santarus (Nasdaq: SNTS), SkinMedica, and GenVault. Prior to launching her entrepreneurial / venture capital career several years ago, Sharon was a tenured Associate Professor in the Department of Orthopedics at the Case Western Reserve University School of Medicine. She is author of over 132 publications, including 2 guest editorships and has made more than 57 presentations to professional audiences. Her clinical training was in veterinary surgery and she is a Diplomate of the American College of Veterinary Surgeons (ACVS). She has served on the governing boards of the ACVS and the Orthopedic Research Society. Sharon has been awarded a MBA from the UCLA Anderson Graduate School of Management; a PhD in Comparative Pathology from UC Davis; and a Master of Science in Veterinary Pathology and Doctor of Veterinary Medicine from The Ohio State University.

In addition to her Okapi responsibilities, Sharon serves on the Board of Governors of the Pardee RAND Graduate School of Public Policy and spends considerable time on a yoga mat.